Navigation Links
Fovea Pharmaceuticals Completes EUR30M Series B Financing
Date:12/12/2007

ing pipeline of products, which will be validated in the clinic using the proceeds of this financing round," said Sander Slootweg, managing partner at Forbion Capital Partners. "We are delighted to invest in Fovea Pharmaceuticals and join an experienced and proven management team along with a very strong and committed group of investors."

In connection with the financing, Sander Slootweg will join the Board of Directors which is comprised of Antoine Papiernik (Sofinnova Partners), Tim Haines (Abingworth), Anthony Wild (Bows Pharmaceuticals) and Bernard Gilly. Bernard Gilly has been elected as Chairman of the Board.

"Fovea's unique product platform has led to the generation of a robust pipeline of promising therapeutic candidates for the treatment of front and back of the eye disorders. Clinical candidates are already in development and at least three new products are expected to progress into the clinic in 2008," commented Pr. Jose-Alain Sahel, Founder of Fovea Pharmaceuticals and Chairman of the Scientific Advisory Board. "It has been a pleasure to work with the talented and productive team at Fovea, and we all look forward to continued progress in exploiting the potential of these novel dedicated therapies."

In parallel to these clinical developments, a strong discovery platform has been implemented, leading to the identification of novel targets. Fovea Pharmaceuticals has recently signed a Research Partnership Agreement with Genzyme to develop gene related therapies on the basis of one of these programs, using Fovea's selected targets to treat major retinal dystrophies.

About FOVEA Pharmaceuticals

Fovea Pharmaceuticals SA (Fovea) is a privately-held biopharmaceutical company specialized in development and commercialization of drugs for the treatment of ocular diseases, with a special focus on retinal pathologies. Created in May 2005, Fovea has a highly experienced board and management team. Fovea has been funded by six leading E
'/>"/>

SOURCE Fovea Pharmaceuticals SA.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and Vanilla ... Forecast (2011 - 2016)," analyzes the chocolate market ... major market drivers, restraints, and opportunities for the chocolate ... global chocolate market is expected to grow from $83.2 ... estimated CAGR of 2.7% from 2011 to 2016. , ...
(Date:10/18/2014)... The Asia-Pacific Bio-based Advanced Phase ... bio-based advanced phase change material market in Asia-Pacific ... through the TOC of the Asia-Pacific Bio-based Advanced ... idea of the in-depth analysis provided. This also ... Asia-Pacific bio-based advanced phase change material market, and ...
(Date:10/18/2014)... 18, 2014 The Asian Electronic Medical Record ... Asian with analysis and forecast of revenue. The electronic medical ... to $2,328.0 million by 2018, at a CAGR of 9.4% ... the Asian Electronic Medical Record (EMR) market, to get an ... glimpse of the segmentation of the market in the same ...
Breaking Biology Technology:Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5
... t2cure, a clinical,stage biopharmaceutical company developing novel regenerative ... it has appointed,Dr. Petra Rueck Head of Clinical ... join our company", said Manfred Ruediger,CEO of t2cure. ... be of critical importance to t2cure as we ...
... DIEGO, Feb. 25 Speid & Associates, a ... hosting,a six session Webinar series on diabetes and ... April. Speakers will include former Food and,Drug Administration ... as,well as a distinguished list of other guest ...
... BOSTON, Feb. 25 Experts from PAREXEL,International ... global,bio/pharmaceutical services provider, will present on key ... Annual EuroMeeting in Barcelona,Spain being held March ... from,presentations by some of PAREXEL,s thought leaders, ...
Cached Biology Technology:Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations 2The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics 2PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 2PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 3PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 4
(Date:10/16/2014)... at William and Mary,s Virginia Institute of Marine ... the Environmental Protection Agency to identify the streams ... to develop tools to help local governments and ... depends critically on a dataset of tidal-marsh observations ... Only with this historical baseline can today,s researchers ...
(Date:10/16/2014)... causes severe respiratory tract infections and worldwide claims ... at VIB and Ghent University have succeeded in ... common virus infection. , Xavier Saelens (VIB/UGent): ... the way for the development of a novel ... causes suffering in numerous small children and elderly ...
(Date:10/15/2014)... to assess the pandemic risk from strains of influenza ... not allow ourselves to become complacent that the most ... of scientists. , Influenza pandemics arise when a new ... develop widespread immunity – spreads in the human population. ... 100 years, the worst of which – the 1918 ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... Drawing on records dating back to the journals of Henry ... plant families near Walden Pond have borne the effects of ... families hit hardest by global warming have included beloved species ... appears this week in the Proceedings of the National ...
... used to treat type 2 diabetes may be more likely ... at Washington University School of Medicine in St. Louis have ... drugs, sulfonylureas, help type 2 diabetics make more insulin, improving ... effects of sulfonylureas are lost after several years of use, ...
... carriers of avian influenza viruses from continent to continent ... has important implications for highly pathogenic avian influenza virus ... multi-pronged research effort to understand the role of migratory ... Asia and North America, scientists with the U.S. Geological ...
Cached Biology News:Effects of climate change vary greatly across plant families 2Moderate use averts failure of type 2 diabetes drugs in animal model 2Genetic evidence for avian influenza movement from Asia to North America via wild birds 2
... to PRKAR2 cAMP is a signaling ... functions. cAMP exerts its effects by activating ... the signal through phosphorylation of different target ... a tetramer composed of two regulatory and ...
...
... a Perkin Elmer UltraVIEW system and want to ... and iQ software? No problem. Our experienced ... your existing microscope, lasers, Sutter filter wheel, Piezo ... work with our precision controller unit and workstation... ...
... instrument is the most advanced thermal cycler ... thermal performance, the Dyad also boasts graphical ... point-and-click navigation via touch pad or mouse. ... and economically expanded to a four-bay system ...
Biology Products: